Annals of Clinical Microbiology and Antimicrobials

Table 3 Microbiological characteristics of transconjugants

From: Genomic insights into the evolution and mechanisms of carbapenem-resistant hypervirulent Klebsiella pneumoniae co-harboring bla_KPC and bla_NDM: implications for public health threat mitigation

Isolate	Carbapenemase	MIC (μg/mL)
Isolate	Carbapenemase	CRO	CAZ	ATM	TZP	ETP	IMP	SXT	AK	GN	CIP	LEV	FOS
J-JNKPN23	NDM-1	≥ 64	≥ 64	4	≥ 128	≥ 8	≥ 16	≥ 16	≥ 64	≥ 16	≤ 0.25	≤ 0.25	≤ 32
J-JNKPN23-1	NDM-1, KPC-2	≥ 64	≥ 64	16	64	≥ 8	≥ 16	≥ 320	≥ 64	≥ 16	≤ 0.25	≤ 0.25	≤ 32
J-JNKPN24	NDM-1	≥ 64	≥ 64	4	≥ 128	≥ 8	≥ 16	≥ 16	≥ 64	≥ 16	≤ 0.25	≤ 0.25	≤ 32
J-JNKPN26-1	NDM-1, KPC-2	≥ 64	≥ 64	4	≥ 128	≥ 8	≥ 16	≥ 320	≥ 64	≥ 16	≤ 0.25	≤ 0.25	≤ 32
J-JNKPN26-2	NDM-1, KPC-2	≥ 64	≥ 64	4	≥ 128	≥ 8	≥ 16	≥ 320	≥ 64	≥ 16	≤ 0.25	≤ 0.25	≤ 32
J-JNKPN26-3	NDM-1, KPC-2	≥ 64	≥ 64	4	≥ 128	≥ 8	≥ 16	≥ 320	≥ 64	≥ 16	≤ 0.25	≤ 0.25	≤ 32
J-JNKPN26-4	NDM-1, KPC-2	≥ 64	≥ 64	4	≥ 128	≥ 8	≥ 16	≥ 320	≥ 64	≥ 16	≤ 0.25	≤ 0.25	≤ 32
J-JNKPN26-5	NDM-1	≥ 64	≥ 64	4	≥ 128	≥ 8	≥ 16	≥ 16	≥ 64	≥ 16	≤ 0.25	≤ 0.25	≤ 32
J-JNKPN29	NDM-1	≥ 64	≥ 64	2	≥ 128	≥ 8	≥ 16	≥ 16	≥ 64	≥ 16	≤ 0.25	≤ 0.25	≤ 32
J-JNKPN30	NDM-1	≥ 64	≥ 64	4	≥ 128	≥ 8	≥ 16	≥ 16	≥ 64	≥ 16	≤ 0.25	≤ 0.25	≤ 32
J-JNKPN31	NDM-1	≥ 64	≥ 64	≥ 64	≥ 128	≥ 8	≥ 16	≥ 16	≥ 64	≥ 16	≤ 0.25	≤ 0.25	≤ 32
J-JNKPN58	KPC-2	≥ 64	≥ 64	≥ 64	≥ 128	≥ 8	≥ 16	≤ 1	≤ 2	≤ 1	≤ 0.25	≤ 0.25	≤ 32

MIC minimal inhibitory concentrations, CRO ceftriaxone, CAZ ceftazidime, ATM aztreonam, TZP piperacillin–tazobactam, ETP ertapenem, IMP imipenem, SXT trimethoprim–sulfamethoxazole, AMK amikacin, GEN gentamicin, CIP ciprofloxacin, LVX levofloxacin

Back to article page

ISSN: 1476-0711

Contact us

Submission enquiries: journalsubmissions@springernature.com